Hospital Mater Dei S.A (MATD3)
B3 Stock Exchange · Brazil · prices in BRL · close of 23 Oct 2026
Key indicators
| Last close | BRL 6.310 |
|---|---|
| 52-week range | 4.180 – 6.850 |
| Return, 1 month / 3 months | +25.0% / +29.6% |
| Return, 1 year / 3 years | +60.0% / −5.9% |
| Trend | Uptrend |
| RSI (14) | 65 |
| Volatility (1 year) | 38.3% |
| Worst drawdown (1 year) | -25.4% |
| Average daily value traded | 1.20M BRL |
| Dividend yield | 2.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Hospital Mater Dei is a Brazilian private healthcare group based in Belo Horizonte that runs general hospitals offering medical and surgical care, intensive care, diagnostic services and cancer treatment. Its patients are mainly private individuals and beneficiaries of health insurance plans, served through hospitals in several Brazilian states. The group also provides outpatient consultations and specialised medical services, and it manages hospital units under its own brand alongside partnerships with other healthcare providers.
On this site Hospital Mater Dei S.A appears as a stock on the B3 Stock Exchange (Brazil), code MATD3, with prices in Brazilian reais (BRL). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Hospital Mater Dei S.A (MATD3) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 6.310 on 23 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 392 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 60.0% and over the last three months it rose 29.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 62 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 18.4% | ||
| From 52-week high | -7.9% | ||
| Momentum | 73 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 29.6% | ||
| 6-month return | 7.3% | ||
| 12-month return, skipping the last month | 28.1% | ||
| Stability (higher is calmer) | 55 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 38.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.4% | ||
| Liquidity | 76 · Strong | Trades actively. | |
| Average daily value traded | 1.20M BRL | ||
| Zero-volume days | 0.0% | ||
| Income | 20 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.4% | ||
| Years with dividends | 4 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +3.4% |
|---|---|
| 1 month | +25.0% |
| 3 months | +29.6% |
| 6 months | +7.3% |
| 1 year | +60.0% |
| 3 years | −5.9% |
| 5 years | −54.2% |
Signals
| 50-day / 200-day average | 5.234 / 5.328 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.262 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 8 Dec 2025 | BRL 0.1505 |
| 13 May 2025 | BRL 0.0749 |
| 30 Apr 2024 | BRL 0.0749 |
| 28 Apr 2023 | BRL 0.0643 |
| 29 Apr 2022 | BRL 0.0900 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.